ALNY FY 2021 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$844M+71.3% YoY

Gross Profit

$704M83.4% margin

Operating Income

-$709M-83.9% margin

Net Income

-$853M-101.0% margin

EPS (Diluted)

$-7.20

Cash Flow

Operating Cash Flow

-$642M

Free Cash Flow

-$718M

Stock-Based Comp.

$166M

Balance Sheet

Total Assets

$3.6B

Total Liabilities

$3.1B

Stockholders' Equity

$588M

Cash & Equivalents

$820M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$844M	$493M	+71.3%
Gross Profit	$704M	$415M	+69.8%
Operating Income	-$709M	-$828M	+14.5%
Net Income	-$853M	-$858M	+0.6%